Improvement in insulin absorption into gastrointestinal epithelial cells by using molecularly imprinted polymer nanoparticles: Microscopic evaluation and ultrastructure

Paul, Pijush; Nopparat, Jongdee; Nuanplub, Mitree; Treetong, Alongkot; Suedee, Roongnapa

doi:10.1016/j.ijpharm.2017.07.071

Cited by 23 publications

(13 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, natural polymers, such as alginate, dextran, cellulose, j-carrageenan, chitosan and mucin, has received much attention as the focus point for effective delivery of oral insulin. For instance, natural biomaterials such as chitosan have been widely favoured in the area of oral insulin delivery due to its positive surface charge, mucoadhesive properties and enhanced permeation properties (Liu et al, 2016;Paul et al, 2017). Unfortunately, the ease of protonation associated with chitosan formulation in acidic environment has reduced its usage in biomedical and pharmaceutical applications.…”

Section: Introductionmentioning

confidence: 99%

Microemulsion-based approach for oral delivery of insulin: formulation design and characterization

Momoh

Kenechukwu

Agbo

et al. 2020

Heliyon

View full text Add to dashboard Cite

Oral delivery of insulin provides a good alternative because it is non-invasive and patient-friendly. However, multiple challenges affected this route. To overcome barriers for oral delivery of insulin, we aimed to develop a novel insulin-loaded microemulsion system based on snail mucin for oral administration. The strategy in the novel system of using mucin loading insulin into the inner core of prepared water in oil microemulsion to provide sustained released, increased in vivo stability and enhanced drug absorption in the gastrointestinal tract. We report how microemulsion composed of varying ratios of snail mucin and Tween® 80 (1:9-9:1) using oil/water emulsion preparation method influenced insulin performance after oral administration. The results obtained include an encapsulation efficiency of above 70 %; in vitro release was sustained over 10 h and in vivo evaluations in diabetic rat model shows that insulin-loaded microencapsulation effectively reduced blood glucose levels over a period >8 h after oral administration. Therefore, we suggest that the developed formulation for oral insulin can be a promising alternative dosage form for oral protein delivery.

show abstract

Section: Introductionmentioning

confidence: 99%

Microemulsion-based approach for oral delivery of insulin: formulation design and characterization

Momoh

Kenechukwu

Agbo

et al. 2020

Heliyon

View full text Add to dashboard Cite

show abstract

“…13,14 Biomimetic drug-imprinted polymer NPs were shown to increase the efficacy of orally administered drugs. 15,16 However, targeting distal postabsorption sites implies the translocation of NPs across the intestinal epithelium. This depends, to a great extent, on the structural integrity of NPs, a further design challenge.…”

Section: Introductionmentioning

confidence: 99%

Praziquantel–lipid nanocapsules: an oral nanotherapeutic with potential <em>Schistosoma mansoni</em> tegumental targeting

Amara¹,

Ramadan²,

El‐Moslemany³

et al. 2018

IJN

View full text Add to dashboard Cite

PurposeLipid nanocapsules (LNCs) have shown potential to increase the bioavailability and efficacy of orally administered drugs. However, their intestinal translocation to distal target sites and their implication in pharmacokinetic (PK)–pharmacodynamic (PD) relationships are yet to be elucidated. In this study, the effect of LNCs on the PD activity and pharmacokinetics of praziquantel (PZQ), the mainstay of schistosomiasis chemotherapy, was investigated.Materials and methodsThe composition of LNCs was modified to increase PZQ payload and to enhance membrane permeability. PZQ–LNCs were characterized in vitro for colloidal properties, entrapment efficiency (EE%), and drug release. PD activity of the test formulations was assessed in Schistosoma mansoni-infected mice 7 days post-oral administration of a single 250 mg/kg oral dose. Pharmacokinetics of the test formulations and their stability in simulated gastrointestinal (GI) fluids were investigated to substantiate in vivo data.ResultsPZQ–LNCs exhibited good pharmaceutical attributes in terms of size (46–62 nm), polydispersity index (0.01–0.08), EE% (>95%), and sustained release profiles. Results indicated significant efficacy enhancement by reduction in worm burden, amelioration of liver pathology, and extensive damage to the fluke suckers and tegument. This was partly explained by PK data determined in rats. In addition, oral targeting of the worms was supported by the stability of PZQ–LNCs in simulated GI fluids and scanning electron microscopy (SEM) visualization of nanostructures on the tegument of worms recovered from mesenteric/hepatic veins. Cytotoxicity data indicated tolerability of PZQ–LNCs.ConclusionData obtained provide evidence for the ability of oral LNCs to target distal post-absorption sites, leading to enhanced drug efficacy. From a practical standpoint, PZQ–LNCs could be suggested as a potential tolerable single lower dose oral nanomedicine for more effective PZQ mass chemotherapy.

show abstract

“…Recently, Paul et al. 324 , 325 developed a biomimetic imprinted nanoparticles to increase self-regulating adhesion and release of insulin by molecular imprinting technique. The imprinted nanoparticles significantly prolonged hypoglycemic effect for up to 24 h and increased insulin transport via transcellular pathway.…”

Section: Current Strategies Towards Enhancement Of the Oral Absorption Of Ppsmentioning

confidence: 99%

Oral delivery of proteins and peptides: Challenges, status quo and future perspectives

Zhu

Chen

Paul

et al. 2021

Acta Pharmaceutica Sinica B

Self Cite

178

View full text Add to dashboard Cite

Proteins and peptides (PPs) have gradually become more attractive therapeutic molecules than small molecular drugs due to their high selectivity and efficacy, but fewer side effects. Owing to the poor stability and limited permeability through gastrointestinal (GI) tract and epithelia, the therapeutic PPs are usually administered by parenteral route. Given the big demand for oral administration in clinical use, a variety of researches focused on developing new technologies to overcome GI barriers of PPs, such as enteric coating, enzyme inhibitors, permeation enhancers, nanoparticles, as well as intestinal microdevices. Some new technologies have been developed under clinical trials and even on the market. This review summarizes the history, the physiological barriers and the overcoming approaches, current clinical and preclinical technologies, and future prospects of oral delivery of PPs.

show abstract

Improvement in insulin absorption into gastrointestinal epithelial cells by using molecularly imprinted polymer nanoparticles: Microscopic evaluation and ultrastructure

Cited by 23 publications

References 34 publications

Microemulsion-based approach for oral delivery of insulin: formulation design and characterization

Microemulsion-based approach for oral delivery of insulin: formulation design and characterization

Praziquantel–lipid nanocapsules: an oral nanotherapeutic with potential <em>Schistosoma mansoni</em> tegumental targeting

Oral delivery of proteins and peptides: Challenges, status quo and future perspectives

Contact Info

Product

Resources

About

Improvement in insulin absorption into gastrointestinal epithelial cells by using molecularly imprinted polymer nanoparticles: Microscopic evaluation and ultrastructure

Cited by 23 publications

References 34 publications

Microemulsion-based approach for oral delivery of insulin: formulation design and characterization

Microemulsion-based approach for oral delivery of insulin: formulation design and characterization

Praziquantel&ndash;lipid nanocapsules: an oral nanotherapeutic with potential <em>Schistosoma mansoni</em> tegumental targeting

Oral delivery of proteins and peptides: Challenges, status quo and future perspectives

Contact Info

Product

Resources

About

Praziquantel–lipid nanocapsules: an oral nanotherapeutic with potential <em>Schistosoma mansoni</em> tegumental targeting